# the SRIW Life Sciences

> the SRIW Life Sciences is a VC fund backing Biotechnology, Medical and Biopharma. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Nov 2022
- Lead investor: 33%
- Last updated: Aug 2026

the SRIW Life Sciences is a VC fund focused on Biotechnology and Medical. the SRIW Life Sciences

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $22M–$23M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Novadip Biosciences | Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $23.4M | Series B | Nov 03, 2022 |  |
| Novadip Biosciences | Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $22.2M | Series B | Oct 28, 2021 |  |
| A-Mansia Biotech | A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host. | $14.3M | Series A | Apr 27, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [CR-CP Life Science Fund](https://shizune.co/investors/profile/cr-cp-life-science-fund) — VC Fund, 2 deals together
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 2 deals together
- [Investsud](https://shizune.co/investors/profile/investsud) — VC Fund, 2 deals together
- [New Science Ventures](https://shizune.co/investors/profile/new-science-ventures) — VC Fund, 2 deals together
- [Vives Louvain Technology Fund](https://shizune.co/investors/profile/vives-fund) — VC Fund, 2 deals together
- [Fonds Vives II (University of Louvain, UCL)](https://shizune.co/investors/profile/fonds-vives-ii-university-of-louvain-ucl) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Life Science Investors in Belgium](https://shizune.co/investors/life-science-investors-belgium)
- [Life Science VC Funds in Belgium](https://shizune.co/investors/life-science-vc-funds-belgium)

## FAQ

### What does the SRIW Life Sciences invest in?

the SRIW Life Sciences invests primarily in Biotechnology, Medical and Biopharma startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is the SRIW Life Sciences's check size?

the SRIW Life Sciences typically joins rounds of $22M–$23M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds the SRIW Life Sciences participates in.

### When did the SRIW Life Sciences last invest?

The most recent investment recorded for the SRIW Life Sciences closed in Nov 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co